News >

Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer

Caroline Seymour
Published: Monday, Mar 25, 2019

Ruta D. Rao, MD

Ruta D. Rao, MD
In tailoring treatment to patients with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer—be it through escalated or de-escalated approaches—the key factors to consider are the patient’s risk for recurrence, how well they’re tolerating the medication, and tumor biology, said Ruta D. Rao, MD.

State of the Science Summit™ on Breast Cancer, Rao, an associate professor at Rush University Medical Center, highlighted the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

OncLive: What studies have informed what is known about the optimal duration of endocrine therapy?

Rao: There are several studies that have informed our knowledge to date. Overall, what we're seeing is that 10 years of endocrine therapy may be superior to 5 years. We have a lot of different options of how to give endocrine therapy, whether it should be 10 years of tamoxifen, 5 years of tamoxifen followed by 5 years of an AI, or other combinations of the 2 therapies.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication